A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

I5T-MC-AACD -

The purpose of this study is to evaluate the effect of LY3002813 on brain scans, evaluate the safety of LY3002813 by looking at adverse events (side effects) and to look at the effect of LY3002813 on the body. The study is for research purposes only and is not intended to treat any medical condition.

Trial Summary

Age Range
≥50 years
Conditions the trial is for
Alzheimer's Disease
What the trial is testing?
Donanemab
Could I receive a Placebo?
Yes
Enrollment Goal
61
Trial Dates
Dec 22, 2015 - Aug 28, 2019
How long will I be in the trial?
Your participation could last up to 84 weeks and include 27 visits to the study center.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.